- Report
- April 2022
- 40 Pages
Saudi Arabia
From €1426EUR$1,500USD£1,198GBP
- Report
- April 2022
- 40 Pages
South Korea
From €1426EUR$1,500USD£1,198GBP
- Report
- April 2022
- 40 Pages
United States
From €1426EUR$1,500USD£1,198GBP
- Report
- April 2022
- 40 Pages
Vietnam
From €1426EUR$1,500USD£1,198GBP
- Report
- March 2022
- 100 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- September 2020
- 700 Pages
Global
From €4658EUR$4,900USD£3,913GBP
- Report
- June 2024
- 90 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- May 2023
- 74 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- September 2022
- 274 Pages
Global
From €3394EUR$3,570USD£2,851GBP
- Book
- November 2015
- 776 Pages
The Autologous Stem Cell market is a subset of the larger Stem Cell market. Autologous stem cells are those derived from the patient's own body, and are used to treat a variety of conditions, including degenerative diseases, autoimmune diseases, and tissue damage. Autologous stem cells are typically harvested from the patient's bone marrow, adipose tissue, or peripheral blood. The cells are then processed and expanded in the laboratory before being re-injected into the patient.
The Autologous Stem Cell market is growing rapidly, driven by advances in stem cell technology and the increasing availability of treatments. The market is expected to continue to expand as more treatments become available and the technology continues to improve.
Some companies in the Autologous Stem Cell market include Osiris Therapeutics, Inc., Athersys, Inc., Mesoblast Limited, and Pluristem Therapeutics, Inc. Show Less Read more